Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

[Adverse effects of new therapeutic approaches in thoracic oncology].

Sammya A, Normand C, Desbaillets N, Coskun M, Goudemant C, Mosimann V, Ferahta N, Christofis M, Serena A, Nikolopoulou A, Abdelhamid K, Stamatiou A, Nguyen-Ngoc T, Bouchaab H, Fleury M, Obeid M, Peters S, Mederos N

[Adverse effects of new therapeutic approaches in thoracic oncology].

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Collet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet